Home

Jeffrey Chodakewitz

CIK 1610876 · EVP GMDA, CMO · last filed 2026-06-23

Jeffrey Chodakewitz is an EVP GMDA, CMO who has filed 65 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing, for ACET, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$30.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $38.3M across reported positions. 37 SEC filings were submitted jointly with VERTEX PHARMACEUTICALS INC / MA.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$38.26M

Companies

7

Total Filings

65

Lifetime Open-Market Net

-$30.85M

Filer Profile

Reported Address
C/O TETRAPHASE PHARMACEUTICALS, INC.
480 ARSENAL ST., SUITE 101
WATERTOWN, MA 02472
Related Filers
VERTEX PHARMACEUTICALS INC / MA — 37 joint filings, latest 2018-04-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACET Director 1,106 $9.52 $10.5K $0 8 2026-06-23
SDGR Director 25,388 $19.02 $482.9K $0 7 2026-06-23
PRAX Director 1,371 $334.58 $458.7K $0 6 2026-06-12
NCNA Director — $1.32 — $0 1 2024-08-23
Adicet Bio, Inc. (TORC) Delisted Director — — — $0 3 2020-06-05
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Director — — — $0 5 2019-06-11
VRTX EVP GMDA, CMO 72,385 $515.44 $37.31M -$30.85M 35 2018-02-14

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 ACET Grant (A) — $0 EDGAR
2026-06-23 SDGR Grant (A) +8,141 $0 EDGAR
2026-06-12 PRAX Grant (A) +1,371 $0 EDGAR
2025-06-27 PRAX Grant (A) — $0 EDGAR
2025-06-20 SDGR Grant (A) +5,997 $0 EDGAR
2025-06-13 ACET Grant (A) +5,900 $0 EDGAR
2024-08-23 NCNA Mixed — $0 EDGAR
2024-06-20 SDGR Grant (A) +5,000 $0 EDGAR
2024-06-07 ACET Grant (A) +5,900 $0 EDGAR
2024-06-06 PRAX Grant (A) — $0 EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.